

Commentary: Transplantation of Dental Pulp Stem Cells Improves Long-Term Diabetic Polyneuropathy together with Improvement of Nerve Morphometrical Evaluation

Keiko Naruse

Department of Internal Medicine, School of Dentistry, Aichi Gakuin University, Japan

Article Info

Article Notes

Received: February 28, 2019

Accepted: May 6, 2019

*Correspondence:

Dr. Keiko Naruse, Department of Internal Medicine, School of Dentistry, Aichi Gakuin University, 2-11 Suemori-dori, Chikusa-ku, Nagoya 464-8651, Japan; Telephone No: +81-52-759-2307; FAX No: +81-52-759-2168; E-mail: narusek@dpc.agu.ac.jp.

© 2019 Naruse K. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License



Diabetic neuropathy is the most common diabetic complication and occurs from the early phase of diabetes, sometimes from the phase of impaired glucose tolerance¹. The onset and progression of diabetic neuropathy are fundamentally linked to metabolic disorders and blood flow impediments resulting from chronic hyperglycemia, with immunological dysfunction and aging as additional contributing factors. The symptoms of diabetic neuropathy are varied and impair quality of life². Furthermore, the presence of diabetic neuropathy associates with mortality³. Although blood glucose control reduces the onset and progression of diabetic neuropathy, sometimes it is not enough for amelioration⁴. There are drugs which reduce the pain-related symptoms. However, the final goal of the treatment with diabetic neuropathy is to improve nerve function and pathological abnormalities with the management of the neuropathic pain⁵⁻⁷. Therefore, more fundamental treatments for diabetic neuropathy are needed.

Our study, entitled “Transplantation of dental pulp stem cells improves long-term diabetic polyneuropathy together with improvement of nerve morphometrical evaluation” has revealed a promising effects of dental pulp stem cell (DPSC) transplantation on diabetic polyneuropathy with a long duration of diabetes⁸. Rats with 52-week duration of diabetes exhibited reductions in the sciatic motor/sensory nerve conduction velocity, nerve blood flow, and intraepidermal nerve fiber density and increases in the current perception threshold in the peripheral nerves. All of which were ameliorated by DPSC transplantation into the hindlimb skeletal muscles.

Cell transplantation using cultured endothelial progenitor cells (EPCs) and mesenchymal stem cells (MSCs), including dental pulp stem cells (DPSCs), ameliorated nerve conduction velocity, nerve blood flow, and intraepidermal nerve fiber density in diabetic animals⁹⁻¹³. However, since most previous studies were of relatively short duration; 2-16 weeks, the morphology in sural nerves did not differ between normal and diabetic animals, except axonal circularity^{10, 14}. To conquer this problem, we harvested long-term (52-week) diabetic rats with low-dose administration of insulin. Our study was the first study which evaluated the effects of stem cell transplantation in animals with a long-term diabetes.

The morphological characteristics of diabetic polyneuropathy include axonal atrophy, nerve demyelination, and reduced regeneration of peripheral sensory nerve fibers¹⁵. In sural nerve biopsies from patients with mild diabetic neuropathy, teased fiber studies revealed paranodal abnormalities, segmental demyelination and remyelination

without axonal degeneration, suggesting that Schwann cell abnormalities precede axonal degeneration¹⁶. Decreases in myelinated fiber density and occupancy were observed in both large and small fibers as the disease progressed^{17, 18}. The long-term diabetic rats in our study demonstrated decreases in the fiber area, occupancy rate, myelin area, and myelin thickness, and an increase in the axonal-to-myelin area ratio, compared with those in the normal rats, suggesting that our long-term diabetic rat model mimics from mild to middle stage of diabetic polyneuropathy in human. The transplantation of DPSCs significantly increased the myelin thickness and area, indicating that the transplantation of DPSCs affected myelin formation in the sural nerve morphology.

Proliferation of rat Schwannoma cells significantly suppressed by polyol pathway activation induced by high glucose condition¹⁹. Cultured Schwann cells from both type 1 and type 2 diabetic mice showed lower production of Nerve growth factor (NGF) and Neurotrophin-3(NT-3) compared to cultured Schwann cells from normal mice²⁰. We previously revealed that high glucose significantly reduced NGF secretion from cultured mouse Schwann cells, which reduced the response on neurite outgrowth²¹. Using rodent Schwann cell culture, we confirmed the effects of DPSC-secreted factors on the proliferation and production of myelin-related protein in Schwann cells. Since Schwann cells maintain peripheral nerve structure and function by ensheathment of unmyelinated axons, myelination of myelinated axons, and secretion of neurotrophic factors²²⁻²⁴, the impact of DPSC transplantation on Schwann cells is crucial for the improvement of diabetic polyneuropathy.

We supposed several therapeutic mechanisms of the DPSC transplantation for diabetic polyneuropathy. The First is neurotrophic effect. Transplantation of DPSCs improved intraepidermal nerve fiber density and myelin thickness in sural nerves of diabetic rats. The second is immunomodulatory effect. DPSC-secreted factors promote macrophages polarization towards anti-inflammatory M2 phenotypes, which result in the suppression of inflammation in the peripheral nerve of diabetic polyneuropathy¹⁴. The third is vasculogenic/angiogenic effect. Some of the transplanted DPSCs still existed in the transplanted site and differentiated into vascular endothelial cells, suggesting that transplanted DPSCs cooperated with the resident cells and induced vasculogenesis¹³. In addition, since DPSC-secreted factors include abundant angiogenic factors, the proliferation of residual endothelial cells may be increased by DPSC transplantation. Transplantation of DPSCs increased capillary/muscle ratio in the skeletal muscles of diabetic rats and increased sciatic nerve blood flow.

On the other hand, the therapeutic efficacy of stem cells was impaired by diabetic condition or aging^{25, 26}. To

avoid these problems, DPSC is an attractive candidate for cell therapy because these are easy to obtain from teeth extracted at an early age by orthodontic reasons without further invasive procedures. Furthermore, the obtained DPSCs may be stem cells before the onset of diabetes. DPSCs can be cryopreserved until they are needed¹³. Allograft is another option. Since most animal experiments in our studies and other studies were allograft, the efficacy of allograft using DPSCs has already been proved. If we can stock DPSCs from many adolescents, DPSCs with less mismatched human leukocyte antigens (HLAs) may be found and used for allograft.

DPSC-secreted factors play a crucial role in DPSC transplantation. The administration of DPSC-conditioned media (DPSC-CM) improved diabetic polyneuropathy²⁷. The therapeutic efficacy of DPSC-CM administration in diabetic polyneuropathy was almost comparable to those of DPSC transplantation. However, the effect of DPSC-CM for motor nerve conduction velocity was lower than that of DPSC transplantation. Furthermore, only DPSC transplantation proved the effects to long-term diabetic polyneuropathy, at present. These results suggest that the application of DPSC transplantation or DPSC-CM administration should be selected depends on the clinical stage of diabetic polyneuropathy. Taken together, DPSC transplantation on diabetic polyneuropathy will provide insights into novel therapeutic strategies for patients with all ages.

Acknowledgements

This work was supported in part by Grant-in-Aid for Scientific Research (21592506) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and in part by the "Strategic Research AGU-Platform Formation (2008-2012)" Project for Private University from MEXT.

References

1. Boulton AJ, Malik RA. Neuropathy of impaired glucose tolerance and its measurement. *Diabetes Care*. 2010; 33: 207-209.
2. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. *Diabetes Care*. 2010; 33: 2285-2293.
3. Tesfaye S. Recent advances in the management of diabetic distal symmetrical polyneuropathy. *J Diabetes Investig*. 2011; 2: 33-42.
4. Gæde P, Vedel P, Parving HH, et al. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. *The Lancet*. 1999; 353: 617-622.
5. Hosseini A, Abdollahi M. Diabetic neuropathy and oxidative stress: therapeutic perspectives. *Oxid Med Cell Longev*. 2013; 2013: 168039.
6. Vinik AI, Casellini CM. Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin. *Diabetes Metab Syndr Obes*. 2013; 6: 57-78.
7. Bondor CI, Veresiu IA, Florea B, et al. Epidemiology of diabetic foot ulcers and amputations in Romania: results of a cross-sectional quality of life questionnaire based survey. *J Diabetes Res*. 2016; 2016.

8. Omi M, Hata M, Nakamura N, et al. Transplantation of dental pulp stem cells improves long-term diabetic polyneuropathy together with improvement of nerve morphometrical evaluation. *Stem Cell Res Ther*. 2017; 8: 279.
9. Naruse K, Hamada Y, Nakashima E, et al. Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. *Diabetes*. 2005; 54: 1823-1828.
10. Shibata T, Naruse K, Kamiya H, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. *Diabetes*. 2008; 57: 3099-3107.
11. Jeong JO, Kim MO, Kim H, et al. Dual angiogenic and neurotrophic effects of bone marrow-derived endothelial progenitor cells on diabetic neuropathy. *Circulation*. 2009; 119: 699-708.
12. Kim BJ, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy. *Lab Anim Res*. 2011; 27: 171-176.
13. Hata M, Omi M, Kobayashi Y, et al. Transplantation of cultured dental pulp stem cells into the skeletal muscles ameliorated diabetic polyneuropathy: therapeutic plausibility of freshly isolated and cryopreserved dental pulp stem cells. *Stem Cell Res Ther*. 2015; 6: 162.
14. Omi M, Hata M, Nakamura N, et al. Transplantation of dental pulp stem cells suppressed inflammation in sciatic nerves by promoting macrophage polarization towards anti-inflammation phenotypes and ameliorated diabetic polyneuropathy. *J Diabetes Investig*. 2016; 7: 485-496.
15. Piao Y, Liang X. Chinese medicine in diabetic peripheral neuropathy: experimental research on nerve repair and regeneration. *Evid Based Complement Alternat Med*. 2012; 2012: 191632.
16. Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. *Diabetologia*. 2005; 48: 578-585.
17. Ohnishi A, Harada M, Tateishi J, et al. Segmental demyelination and remyelination in lumbar spinal roots of patients dying with diabetes mellitus. *Ann Neurol*. 1983; 13: 541-548.
18. Sima AA, Bril V, Nathaniel V, et al. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. *N Engl J Med*. 1988; 319: 548-555.
19. Kamiya H, Nakamura J, Hamada Y, et al. Polyol pathway and protein kinase C activity of rat Schwannoma cells. *Diabetes Metab Res Rev*. 2003; 19: 131-139.
20. Dey I, Midha N, Singh G, et al. Diabetic Schwann cells suffer from nerve growth factor and neurotrophin-3 underproduction and poor associability with axons. *Glia*. 2013; 61: 1990-1999.
21. Tosaki T, Kamiya H, Yasuda Y, et al. Reduced NGF secretion by Schwann cells under the high glucose condition decreases neurite outgrowth of DRG neurons. *Exp Neurol*. 2008; 213: 381-387.
22. Bunge RP. Expanding roles for the Schwann cell: ensheathment, myelination, trophism and regeneration. *Curr Opin Neurobiol*. 1993; 3: 805-809.
23. Sharghi-Namini S, Turmaine M, Meier C, et al. The structural and functional integrity of peripheral nerves depends on the glial-derived signal desert hedgehog. *J Neurosci*. 2006; 26: 6364-6376.
24. Mizisin AP. Mechanisms of diabetic neuropathy: Schwann cells. *Handb Clin Neurol*. 2014; 126: 401-428.
25. Kim H, Han JW, Lee JY, et al. Diabetic mesenchymal stem cells are ineffective for improving limb ischemia due to their impaired angiogenic capability. *Cell Transplant*. 2014; 8: 8.
26. Kondo M, Kamiya H, Himeno T, et al. Therapeutic efficacy of bone marrow-derived mononuclear cells in diabetic polyneuropathy is impaired with aging or diabetes. *J Diabetes Investig*. 2015; 6: 140-149.
27. Makino E, Nakamura N, Miyabe M, et al. Conditioned media from dental pulp stem cells improved diabetic polyneuropathy through anti-inflammatory, neuroprotective and angiogenic actions: Cell-free regenerative medicine for diabetic polyneuropathy. *J Diabetes Investig* [Epub ahead of print].